Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial - Concepedia

Concepedia

Publication | Closed Access

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

924

Citations

25

References

2009

Year

Kathleen Hawker, Paul O’Connor, Mark S. Freedman, Peter A. Calabresi, Jack P. Antel, Jack H. Simon, Stephen L. Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,

Annals of Neurology

Abstract

Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B-cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions.

References

	Year	Citations
Rating neurologic impairment in multiple sclerosis John F. Kurtzke Neurology	1983	14.7K
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis W. I. McDonald, Alistair Compston, Gilles Edan, Annals of Neurology	2001	6.9K
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold, New England Journal of Medicine	2008	2.4K
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 ME Reff, K Carner, KS Chambers, Blood	1994	1.9K
Identification of autoantibodies associated with myelin damage in multiple sclerosis Claude P. Genain, Barbara Cannella, Stephen L. Hauser, Nature Medicine Autoimmune DiseaseAutoantibody ProductionNeurological DisorderMedicineImmunology	1999	888
Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system Jonathan P. Godbout, J. Chen, J. Abraham, The FASEB Journal AgingImmunologyInnate ImmunityExaggerated NeuroinflammationAcute Cognitive Impairment	2005	803
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial Amit Bar‐Or, Peter A. Calabresi, Douglas L. Arnold, Annals of Neurology	2008	524
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Ludwig Kappos, Mark S. Freedman, Chris H. Polman, The Lancet Disease ProgressionNeurological DisorderClinical TrialsBenefit StudyBeta-1b Treatment	2007	499
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial Jerry S. Wolinsky, Ponnada A. Narayana, Paul O’Connor, Annals of Neurology	2007	423
Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system Chén Jìng, Jessica B. Buchanan, Nathan L. Sparkman, Brain Behavior and Immunity InflammationPsychoneuroimmunologyAcute StimulationMedicineImmunology	2007	392

Page 1